Hyperlipidemia in a myeloma patient after bortezomib treatment

We read with great interest the article by Gotoh et al. [1], inwhich they reported about a multiple myeloma patient refractory to VAD therapy who developed hyperlipidemia (total cholesterol, TC, 388 mg/dl and triglycerides, TG, 411 mg/dl) and multiple lipoma after two courses of Bortezomib, dexamethasone. We would like to share some experience and raise few questions about it.